Search for a trial

An open label phase IIa trial to assess efficacy and tolerability of a once a week oral dose of 200 mg R126638 in disto-lateral toenail onychomycosis.

The objective of this open label phase IIa trial is to evaluate the efficacy and tolerability of a once a week dose of 200 mg R126638, for a maximum of 12 weeks, for the treatment of toenail onychomycosis.

The influence of mannose-binding lectin (MBL) on the course of disease in patients with cystic fibrosis (CF).

1. To study the possible association between MBL-deficiency and the occurence and severity of infections in MBL-deficient CF patients.2. To study the possible association between MBL-deficiency and the severity of cystic fibrosis.3. To study the…

A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400 mg once daily to intravenous piperacillin/tazobactam 4.0/0.5 g every 8 hours followed by oral amoxicillin/clavulanic acid tablets 875/125 mg every 12 hours for the treatment of subjects with complicated skin and skin structure infections

The primary objective of the study is to reject the Null hypothesis: A 7 to 21 day therapy with moxifloxacin, 400 mg once daily is more than 10 % less effective than a 7 to 21 day therapy with piperacillin/tazobactam three times daily possibly…